{"nctId":"NCT00416520","briefTitle":"A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia","startDateStruct":{"date":"2007-06"},"conditions":["Chronic Kidney Disease","Hyperphosphatemia"],"count":336,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®)"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"3","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Another phosphate binder (Sevelamer)"]}],"interventions":[{"name":"MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®)","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Another phosphate binder (Sevelamer)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female, 18 years of age or over\n* Clinically stable haemodialysis or peritoneal dialysis\n* Stable phosphate control\n* On a stabilised phosphorus diet\n* Female and of child-bearing potential have a negative serum pregnancy test.\n* Male subjects must agree to use appropriate contraception.\n\nExclusion Criteria:\n\n* Current clinically significant medical comorbidities, which may substantially compromise subject safety, or expose them to undue risk, or interfere significantly with study procedures and which, in the opinion of the Investigator, makes the subject unsuitable for inclusion in the study.\n* Body Mass Index (BMI) \\<=16.0 kg/m2 or \\>=40.0 kg/m2\n* A current or history of significant gastrointestinal motility problems\n* A positive test for HIV 1 and 2 antibodies\n* A history of substance or alcohol abuse within the last year.\n* Seizure disorders\n* A history of drug or other allergy\n* A temporary catheter as a vascular access\n* Participated in a clinical study with any experimental medication in the last 30 days or an experimental biological product within the last 90 days prior to signing of informed consent","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Serum Phosphorus Levels From Week 12 to Week 16 (LOCF) (ITT2)","description":"ITT2 population included all re-randomised subjects who completed 12 weeks in the MCI-196 treatment group and received at least 1 dose of study medication in the placebo-controlled withdrawal period and had at least 1 central serum phosphorus value after 12 weeks.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.24","spread":"1.46"},{"groupId":"OG001","value":"1.27","spread":"1.48"}]}]}]},{"type":"SECONDARY","title":"Change in Serum Phosphorus Levels From Baseline to Week 12 (LOCF) (ITT1)","description":"ITT1 population included all subjects who received a randomisation number (at Week 0), took at least 1 dose of study medication and had at least 1 central serum phosphorus value after the start of study medication.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.12","spread":"1.63"},{"groupId":"OG001","value":"-2.16","spread":"1.55"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":26,"n":162},"commonTop":["Diarrhoea","Vomiting","Nausea","Constipation","Hypertension"]}}}